OSE Immunotherapeutics: End of a concerted action between shareholders

On September 30, 2025, the group formed by Mr. Emile Loria, Ms. Dominique Costantini, Mr. Alexis Peyroles, MS Medical Synergy SA and Aperana Consulting SARL crossed downwards the thresholds of 20%, 15%, 10% and 5% of the capital and voting rights of OSE Immunotherapeutics. This decrease results from the end of their concerted action, caused by the termination of the shareholders' agreement. The latter had been established on May 27, 2025 and ended automatically after the combined general meeting of September 30, 2025.

Following this transaction, Ms. Dominique Costantini holds 9.16% of the capital and 13.84% of the voting rights. Mr. Emile Loria holds 6.80% of the capital and 5.48% of the voting rights. Alexis Peyroles, via Aperana Consulting, holds a total of 1.31% of the capital and 2.10% of the voting rights. This change marks a redistribution of stakes within the company.